Exagen (XGN) to Release Quarterly Earnings on Monday

Key Points

• Exagen will report Q1 2026 results before the market opens on May 4, 2026, with analysts projecting ($0.22) EPS and about $16.3 million in revenue; the earnings call is scheduled for 8:30 AM ET.
• Last quarter the company reported ($0.20) EPS and $16.63 million in revenue, but remains unprofitable (negative ROE and net margin), and analysts forecast -$1 EPS for the current fiscal year and $0 for the next.
• Despite low share prices (~$2.70) and recent insider selling by the CEO, Wall Street shows a mostly positive view (nine Buys, one Sell) with a consensus price target of $9.38, and institutional investors own roughly 75% of the stock.

Exagen (NASDAQ:XGN - Get Free Report) is expected to be issuing its Q1 2026 results before the market opens on Monday, May 4th. Analysts expect the company to announce earnings of ($0.22) per share and revenue of $16.3230 million for the quarter. Parties may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Monday, May 4, 2026 at 8:30 AM ET.

Exagen (NASDAQ:XGN - Get Free Report) last announced its earnings results on Tuesday, March 10th. The company reported ($0.20) EPS for the quarter, meeting the consensus estimate of ($0.20). The company had revenue of $16.63 million for the quarter, compared to analyst estimates of $16.46 million. Exagen had a negative return on equity of 105.03% and a negative net margin of 29.97%. On average, analysts expect Exagen to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Exagen Stock Performance

NASDAQ:XGN opened at $2.70 on Monday. The company has a current ratio of 3.45, a quick ratio of 3.45 and a debt-to-equity ratio of 1.39. The stock has a market capitalization of $64.94 million, a price-to-earnings ratio of -2.93 and a beta of 1.93. The firm has a fifty day simple moving average of $3.13 and a two-hundred day simple moving average of $5.88. Exagen has a 12 month low of $2.59 and a 12 month high of $12.23.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on XGN. B. Riley Financial reaffirmed a "buy" rating and issued a $8.00 price target (down from $18.00) on shares of Exagen in a research report on Friday, January 30th. TD Cowen dropped their price target on shares of Exagen from $13.00 to $10.00 and set a "buy" rating on the stock in a research report on Tuesday, February 24th. BTIG Research dropped their price target on shares of Exagen from $10.00 to $9.00 and set a "buy" rating on the stock in a research report on Tuesday, March 10th. UBS Group set a $10.00 price target on shares of Exagen in a research report on Wednesday, March 11th. Finally, Canaccord Genuity Group dropped their price target on shares of Exagen from $10.00 to $8.00 and set a "buy" rating on the stock in a research report on Monday, April 20th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Exagen presently has an average rating of "Moderate Buy" and a consensus price target of $9.38.

Insider Buying and Selling at Exagen

In other news, CEO John Aballi sold 15,698 shares of the business's stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $3.62, for a total value of $56,826.76. Following the sale, the chief executive officer owned 687,299 shares of the company's stock, valued at $2,488,022.38. The trade was a 2.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 12.60% of the stock is owned by corporate insiders.

Institutional Trading of Exagen

Several hedge funds and other institutional investors have recently modified their holdings of XGN. Acadian Asset Management LLC bought a new position in shares of Exagen in the 1st quarter worth $25,000. Truvestments Capital LLC raised its position in shares of Exagen by 109.5% during the 4th quarter. Truvestments Capital LLC now owns 6,169 shares of the company's stock valued at $38,000 after buying an additional 3,225 shares in the last quarter. Persistent Asset Partners Ltd purchased a new stake in shares of Exagen during the 4th quarter valued at $80,000. Jain Global LLC purchased a new stake in shares of Exagen during the 4th quarter valued at $82,000. Finally, Schonfeld Strategic Advisors LLC purchased a new stake in shares of Exagen during the 4th quarter valued at $82,000. Institutional investors own 75.25% of the company's stock.

Exagen Company Profile

Exagen Inc is a molecular diagnostics company focused on improving the detection and management of autoimmune diseases. Headquartered in the United States, the company develops, manufactures and markets laboratory tests designed to help clinicians address diagnostic challenges associated with complex connective tissue disorders.

The company's flagship product portfolio, marketed under the Avise® brand, includes multi-analyte assays such as the Avise® Connective Tissue Disease (CTD) panel, Avise® Lupus panel and Avise® Sjögren's panel.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.